Gene
RNF43
RNF43 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (11), Actionable biomarkers (1), Trial mentions (13), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention RNF43. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 6 of 11,460 | 0.05% |
| 2022 | 1 of 8,285 | 0.01% | 10 of 13,598 | 0.07% |
| 2021 | 3 of 8,692 | 0.03% | 8 of 15,045 | 0.05% |
| 2020 | 1 of 7,640 | 0.01% | 7 of 14,459 | 0.05% |
| 2019 | 2 of 7,300 | 0.03% | 2 of 12,159 | 0.02% |
| 2018 | 0 of 6,927 | 0.00% | 10 of 11,854 | 0.08% |
| 2017 | 0 of 6,558 | 0.00% | 9 of 11,595 | 0.08% |
Showing 10 of 37 years.
Assay-provider ledger (11)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| University of Pittsburgh Medical Center | Not a company | Clinical validation | 1 | April 01, 2026 |
| Geneplus-Beijing Institute | Diagnostic provider | No clinical or analytical validation recorded for this pair | 1 | December 01, 2020 |
| AB Applied Biosystems | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | May 01, 2019 |
| Broad Institute | Not a company | Clinical validationAnalytical validation | 2 | May 01, 2019 |
| Life Technologies | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | May 01, 2019 |
Showing 5 of 11 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| RNF43 oncogenic mutation | Porcupine Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (13)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05420064 | Trial eligibility (AACT) |
| NCT02278133 | Trial eligibility (AACT) |
| NCT04681248 | Trial eligibility (AACT) |
| NCT04851119 | Trial eligibility (AACT) |
| NCT04907539 | Trial eligibility (AACT) |
Showing 5 of 13 trial mentions.
Target-disease associations (335)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormal bleeding | phenotype | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Acromesomelic dysplasia, Grebe type | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - myelodysplastic syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 335 associations.
Vendor sourcing (57)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The p.R307Q variant (also known as c.920G>A), located in coding exon 7 of the RNF43 gene, results from a G to A substitution at nucleotide position 920. The ... | View ClinVar record SCV003540314.3 |
| Array BioPharma (United States) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Male or female aged ≥ 18 years * Histological or cytological confirmed metastatic colorectal cancer * Written documentation of KRAS wild-type status and... | View trial NCT02278133 |
| Array BioPharma (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | RNF43 | View trial NCT02278133 |
| Children's Oncology Group | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * PART A: Patients must be \>= 12 months and =\< 21 years of age at the time of study enrollment * PART B: Patients must be \>= 12 months and =\< 30 years... | View trial NCT04851119 |
| Children's Oncology Group | Trial sponsor | Mentioned in trial textTrial free-text mention | RNF43 | View trial NCT04851119 |
Showing 5 of 57 sourcing records.
Trial-cited literature (74)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications. | Genome medicine | 2025 | 5 |
| Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial. | Anticancer research | 2025 | 2 |
| Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. | BMC medicine | 2024 | 38 |
| Transposable elements mediate genetic effects altering the expression of nearby genes in colorectal cancer. | Nature communications | 2024 | 16 |
| Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. | World journal of gastrointestinal surgery | 2023 | 195 |
Showing 5 of 74 papers.
Protein variant mentions (15)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.C511F | 1 | 2018 | PMID 29500184 |
| p.K559Q | 1 | 2015 | PMID 25741868 |
| p.L214V | 1 | 2015 | PMID 25741868 |
| p.N1313S | 1 | 2018 | PMID 29500184 |
| p.P372S | 1 | 2015 | PMID 25741868 |
Showing 5 of 15 variants.
Literature-extracted relations (12)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Colorectal Neoplasms | Disease | associate |
Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial. | 2025 |
| Pulmonary Atelectasis | Disease | associate |
Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial. | 2025 |
| Cholangiocarcinoma | Disease | associate |
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. | 2024 |
| Calcinosis Cutis | Disease | associate |
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. | 2023 |
| Colorectal Neoplasms | Disease | associate |
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. | 2023 |
Showing 5 of 12 relation assertions.
Organizations publishing (154)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 6 | 2015 to 2021 |
| The University of Texas System | Academic | 6 | 2020 to 2023 |
| Harvard Medical School | Academic | 5 | 2015 to 2024 |
| Mass General Brigham | Hospital | 5 | 2015 to 2018 |
| The Netherlands Cancer Institute | Hospital | 5 | 2015 to 2025 |
Showing 5 of 154 organizations.
Where RNF43 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- infectious disease
- measurement
- nervous system disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
298 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.